Every 8-K that Keen Vision Acquisition Corporation Units (KVACU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KVACU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KVACU filings page.
Keen Vision Acquisition Corporation reported that Nasdaq notified it on July 27, 2026 that its units, ordinary shares, and warrants will be suspended and delisted from the Nasdaq Global Market for failing to meet listing standards, including key special purpose acquisition company requirements.
The notice cites non-compliance with Nasdaq IM-5101-2, which requires completing a business combination within 36 months of IPO registration effectiveness, and minimum thresholds of 1,100,000 publicly held shares and 400 total holders. Trading is scheduled to be suspended on August 3, 2026, with a Form 25-NSE to remove the securities from listing and registration. The company will not appeal and expects its securities to trade over-the-counter, intending to seek a new Nasdaq listing in connection with a potential business combination.
Keen Vision Acquisition Corporation entered into a financing arrangement with its sponsor to extend the time it has to complete a business combination.
On April 21, 2026, the company issued an unsecured promissory note for $120,000 to KVC Sponsor LLC. The sponsor deposited the same amount into the company’s trust account, allowing the business combination deadline to be extended. The note bears no interest and becomes due at the closing of a business combination. The holder may convert the note into units identical to the IPO units at $10.00 per unit. By depositing $120,000 into the trust account on April 27, 2026, the company extended its business combination period to July 27, 2026.
Keen Vision Acquisition Corporation reported that it amended its binding letter of intent with Medera Inc. and its subsidiary Novoheart Group Limited. The amendment moves the target date to sign a new replacement merger agreement from April 10, 2026 to April 30, 2026.
The prior merger agreement dated September 3, 2024 had already been terminated and replaced by this letter of intent. The parties continue to use their best efforts to finalize and execute the replacement merger agreement by the new deadline.
Keen Vision Acquisition Corporation entered into a binding letter of intent with Medera Inc. and its subsidiary Novoheart Group Limited (NVH) to negotiate a replacement merger agreement. The new deal would combine NVH, a pre-clinical human disease modeling and drug discovery business, with Keen Vision, which would remain Nasdaq-listed.
The LOI sets NVH’s enterprise valuation at US$100,000,000 and requires the surviving company to have at least US$10,000,000 of available cash at closing after expenses and NVH-related debt. Cash expenses paid at closing are capped at US$700,000 for Keen Vision and US$1,300,000 for NVH, with liquidity coming from the trust account after redemptions, any PIPE financing, and NVH’s cash.
The parties aim to sign the replacement merger agreement by April 10, 2026, with closing conditions largely mirroring a prior merger agreement that has now been terminated under a mutual release. The deal must close within nine months of the LOI, and any PIPE fundraising must also be completed within nine months of signing.